Recent data has also identified MET amplification as a recurrent mechanism of resistance to targeted therapy in RET fusion subset of NSCLC as 15% of patients who develop resistance to RET inhibitors harbor acquired MET amplification without concurrent RET resistance mutations [53]. Here, MET is linked to non-small cell lung carcinoma.